ArticleBMC cancer2025
A retrospective case series at a tertiary hospital in china: ultrasonographic features of Struma ovarii.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of ultrasound features and clinical manifestations of struma ovarii.Frontiers in oncology · 2026Article
- Recurrent Malignant Struma Ovarii With Peritoneal Implants Following Prior Thyroid Carcinoma Treatment.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAlthough struma ovarii (SO) is mostly benign, it is frequently overtreated due to challenges in differentiating it from malignant tumors. Therefore, the purpose of this study was to investigate the clinical, laboratory, ultrasonographic, and pathological characteristics of SO to improve the accuracy of preoperative diagnosis.
methodsWe retrospectively reviewed the clinical data and imaging characteristics of 103 patients with postoperative pathology for SO at the Affiliated Hospital of Qingdao University from May 2013 to November 2023.
resultsAmong the 103 patients diagnosed with SO, 95 were benign SO (median age: 44.9 years (range, 15-83 years)) and 8 were malignant struma ovarii (MSO) (49.6 years (range, 15-83 years)), malignant cases accounted for 7.8% of the cohort. No statistically significant difference was observed in the median age between patients with benign SO and those with MSO (p = 0.346). Approximately 52.4% of SO patients had an increase in CA125, while CEA, AFP, HE4 and CA199 were basically within the normal range, and these markers had no clinical significance. The ultrasound manifestations were mostly cystic masses or predominantly cystic-solid masses (78/98), and 18 cases were solid masses or predominantly solid-cystic masses. Two patients showed negative results on ultrasound examination and was discovered during another gynecological surgery. Most of the masses are completely separated and multilocular, most with smooth outer margins. Nearly one-half of the masses have punctate or short-line echoes with comet tails, papillary protrusions can be seen on the inner wall of some lesions, and there is usually no blood flow inside the tumor or only a few dotted blood flow signals (79/96). Among the 6 patients with MSO which have ultrasound imaging, 4 patients showed a multilocular cystic mass on ultrasound, with poor sound echo in the cystic part, and 2 patients showed a solid mass on ultrasound with abundant blood flow signals. Immunohistochemistry results showed positive expression rates for thyroid transcription factor-1 (TTF-1) (96%, 24/25), thyroglobulin (TG) (90.5%, 19/21), PAX8 (94.7%, 18/19), and Ki-67 (100% 16/16), though Ki-67 expression levels were generally low, with 15 cases < 5% and 1 case at 50%.
conclusionUltrasonographic features-including multilocular cystic-solid masses with septations, hyperechoic "pearl signs," and comet-tail artifacts-may raise suspicion for SO. However, differentiating between benign and malignant cases remains challenging due to significant imaging overlap. A multimodal diagnostic approach incorporating clinical presentation, laboratory findings, and histopathological evaluation is essential for accurate diagnosis and optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.